南方錳業(01091.HK)擬折讓約18.55%配售最多8.23億股 籌資約1.8億港元
格隆匯7月8日丨南方錳業(01091.HK)發佈公吿,於2025年7月8日,公司與配售代理訂立配售協議,公司擬配售最多8.23億股配售股份,配售股份相當於:(a)於本公吿日期已發行股份總數的20%;及(b)經配發及發行配售股份擴大後的已發行股份總數約16.67%。配售價為每股配售股份0.224港元,較股份於配售協議日期在聯交所所報收市價每股0.275港元折讓約18.55%。
配售事項所得款項淨額預期為約180.44百萬港元,公司擬將配售所得款項淨額全數用於償還集團的未償還銀行貸款。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.